The startup is developing therapeutics for drug-resistant cancers — and applying its technology to other arenas, including Covid-19.
Image: MiRecule CEO Anthony Saleh, shown here in 2018, views protein molecules in a silver stained gel. JOANNE S. LAWTON
{iframe}https://www.bizjournals.com/washington/news/2021/05/24/exclusive-mirecule-rna-therapy-cancer-funding.html{/iframe}